Itovebi (inavolisib) / Roche - LARVOL DELTA

Phase I/Ib study of inavolisib (INAVO) + bevacizumab (BEV) or cetuximab (CETUX) for PIK3CA-mutated (mut) metastatic colorectal cancer (mCRC). (ASCO-GI 2026) - P1 | "Funded by F. Hoffmann-La Roche Ltd Clinical Trial Registration Number: NCT04929223 The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST."

Metastases • P1 data • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • PIK3CA

A prospective, direct-to-patient study to evaluate clinical and molecular mechanisms of resistance to capivasertib in estrogen receptor-positive metastatic breast cancer (SABCS 2025) - "PI3Kα inhibitors including alpelisib and inavolisib improve progression free survival (PFS) in PIK3CA-mutated ER+ MBC, but are often associated with high-grade toxicities such as hyperglycemia...In the CAPItello-291 trial, capivasertib combined with fulvestrant more than doubled PFS to 7.3 months versus 3.1 months with fulvestrant alone, and exhibited a favorable toxicity profile...Since January 2025, 10 patients have been enrolled and provided pre-treatment ctDNA samples. Further study details are available at https://contributeher.wixsite.com/capivaresistance."

Clinical • Metastases • Breast Cancer • Estrogen Receptor Positive Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • AKT1 • ER • PIK3CA • PTEN

Investigating association of comorbidities and race with all-cause mortality outcomes of PI3K inhibitor use in metastatic breast cancer (mBC) (SABCS 2025) - "PI3K and AKT pathway inhibitors Alpelisib, Inavolisib, and Capivasertib (PI3K/AKTi) are FDA approved treatments with demonstrated significant clinical benefit, improving progression free survival for Hormone receptor positive (HR+) mBC. We did not identify disparities in mortality between our 3 racial cohorts. Future studies are needed to understand interactions between individual PI3K/AKTi agents and comorbidities to inform appropriate management strategies and ultimately improve patient outcomes."

Metastases • Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor

First Preclinical Evaluation of Inavolisib-Based Combinatorial Strategies in PIK3CA-Mutant Breast Cancer Brain Metastasis Models (SABCS 2025) - "For TNBC models, combinations included PD-1 antibody and albumin-bound paclitaxel. For HER2-positive models, Inavolisib was combined with Trastuzumab + Pertuzumab, T-DXd (Trastuzumab deruxtecan), or Tucatinib...This study provides the first preclinical evidence of Inavolisib-based combination strategies in PIK3CA-mutant breast cancer brain metastases, using both novel intracranial animal models and PDX systems. Our results suggest that: Inavolisib combined with PD-1 antibody is a promising regimen for TNBC with brain metastases; Inavolisib + T-DXd or Trastuzumab + Pertuzumab shows potent activity in HER2-positive BCBM. These findings highlight the potential of PI3K-targeted combinatorial strategies for overcoming the BBB challenge in breast cancer brain metastases and provide a strong rationale for clinical translation."

IO biomarker • Preclinical • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • HER-2 • PIK3CA

ReDiscover-2, a phase 3 study of RLY-2608 + fulvestrant versus capivasertib + fulvestrant as treatment for locally advanced or metastatic PIK3CA-mutant HR+/ HER2- breast cancer following recurrence or progression on or after treatment with a CDK4/6 inhibitor (trial in progress) (SABCS 2025) - P3 | "While the PI3K inhibitors alpelisib and inavolisib and the AKT inhibitor capivasertib have been approved by the FDA to treat this substantial patient population, these therapies cause significant toxicity, notably hyperglycemia, rash, and diarrhea, due to their non-selective targeting of the pathway. Type 1 diabetes, or Type 2 diabetes requiring antihyperglycemic medication are excluded• No prior PI3K, AKT, or mTOR inhibitors or any agent whose mechanism of action is to inhibit the PI3K/AKT/mTOR pathwayReDiscover-2 (NCT06982521) is open for enrollment. For further information, contact: clinicaltrials@relaytx.com."

Metastases • P3 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2 • PIK3CA • PTEN

Morpheus-TNBC: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - P1/2 | N=792 | Recruiting | Sponsor: Hoffmann-La Roche | N=580 ➔ 792 | Trial completion date: May 2028 ➔ Sep 2030 | Trial primary completion date: May 2028 ➔ Sep 2030

Enrollment change • Trial completion date • Trial primary completion date • Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • HER-2 • PD-L1 • PIK3CA

Implications of PIK3CA/HER2 Status and Age/Comorbidities on Clinical Investigators' (CIs) Selection of First-Line Systemic Therapy for Hormone Receptor-Positive (HR+) Metastatic Breast Cancer (mBC) (SABCS 2025) - "A modest honorarium was offered. Ribociclib (R) was the most common CDKi recommended for PIK3CA-wildtype, HER2-negative tumors, including patients with symptomatic visceral and asymptomatic bone metastases (Table). For patients with PIK3CA-mutated tumors with disease relapse 2 years into adjuvant endocrine therapy (ET), respondents most commonly recommended inavolisib (I)/palbociclib (P)/ET, and of great interest, 7 of 20 CIs would recommend this triplet for a patient with de novo disease. For patients with HR+, HER2-positive tumors, P/ET in addition to trastuzumab/pertuzumab was the most common recommendation for postchemotherapy/anti-HER2 maintenance treatment... The clinical practice trend of selecting R as the preferred initial CDKi because of its consistent overall survival benefit has been modified by data from INAVO120 and PATINA, in which the perceived better tolerability of P led to its combination with targeted therapies that significantly improved outcomes...."

Clinical • Metastases • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2 • PIK3CA

MODULE 3: Evolving Up-Front Treatment Paradigm for HR-Positive, HER2-Negative Metastatic Breast Cancer (mBC) (SABCS 2025) - "Sponsored by Genentech, a member of the Roche Group, Eli Lilly and Stemline Therapeutics Inc. Optimal approach to and timing of the assessment of relevant biomarkers for patients with HR-positive mBC; increasing relevance of biomarker evaluation in the up-front setting Long-term follow-up from pivotal clinical trials and other relevant research efforts, such as the RIGHT Choice and ABIGAIL trials, evaluating CDK4/6 inhibitors for HR-positive, HER2-negative mBC; factors affecting the selection of a CDK4/6 inhibitor and an endocrine partner Key findings from the Phase III INAVO120 study evaluating inavolisib in combination with palbociclib and fulvestrant as first-line therapy for patients with HR-positive, HER2-negative mBC with a PIK3CA mutation whose disease had progressed during or within 12 months of adjuvant endocrine therapy FDA approval of inavolisib/palbociclib/fulvestrant and clinical role in the treatment of newly diagnosed HR-positive, HER2-negative mBC with a..."

Metastases • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ER • HER-2 • PIK3CA

PIK3R1 (p85α) alterations define a targetable subset of breast cancer with broad sensitivity to PI3K and AKT inhibitors (SABCS 2025) - "Strikingly, PIK3R1 mutations conferred pan-sensitivity to active-site PI3Ki (alpelisib, inavolisib), AKTi (capivasertib), and mutant-selective PI3Ki (STX-478, RLY-2608) in vitro. This is the first comprehensive study of PIK3R1 alterations in breast cancer. Our findings establish PIK3R1 as a functional driver of oncogenic PI3K signaling and show that PIK3R1 alterations confer sensitivity to both established and investigational PI3K and AKT inhibitors. These findings nominate PIK3R1 alterations as an actionable genomic biomarker and support the inclusion of patients with PIK3R1-altered breast cancer in clinical trials testing PI3K and AKT inhibitors."

Breast Cancer • Estrogen Receptor Positive Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • AKT1 • ER • PIK3CA • PIK3R1 • PTEN

Real World Experience of PIK3CA, AKT inhibitors, and oral SERD in patients with hormone receptor positive metastatic breast cancer (SABCS 2025) - "Result A total of 107 patients who had PIK3CA pathway alteration and received PI3CK/AKT inhibitors were identified: fulvestrant alpelisib (N=51), fulvestrant capivasertib (N=35), inavolisib (N=2), 2 or more PIK3CA/AKT inhibitors (N=11), and PIK3CA/AKT inhibitors and Elacestrant (N=8). Our study is limited by its small sample size, and we observed most patients with ESR1 and PIK3CA pathway co-mutation were able to benefit from sequential therapy of oral SERD or PIK3CA pathway inhibitors, whichever treatment comes first, and showed a favorable response to either treatment. Future effort for a multi-institutional study is planned."

Clinical • Metastases • Real-world • Real-world evidence • Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ATM • BRCA1 • CDH1 • CHEK2 • ER • PIK3CA

Functional analysis of gedatolisib combined with fulvestrant and/or palbociclib in breast cancer cell models adapted to estrogen receptor and/or CDK4/6 inhibitors (SABCS 2025) - " Gedatolisib (pan-PI3K, mTORC1/2 inhibitor), inavolisib (PI3Kα inhibitor), capivasertib (AKT inhibitor) were tested as single agents or in combination with fulvestrant and/or palbociclib in treatment-naïve BC cell lines with or without PIK3CA mutations as well as in BC cell lines adapted to long-term treatment with fulvestrant and/or palbociclib. These results indicate that gedatolisib plus fulvestrant, with and without palbociclib, effectively controls the growth of treatment-naïve BC cells as well as BC cells adapted to palbociclib/fulvestrant treatment. Moreover, in contrast to the currently approved PI3Kα and AKT inhibitors, the gedatolisib/palbociclib/fulvestrant triplet is effective in BC cells with or without PIK3CA mutations. The combination of gedatolisib with ET and a CDK4/6 inhibitor is being evaluated in two ongoing Phase 3 clinical trials as first-line (VIKTORIA-2) or second-line (VIKTORIA-1) treatment of HR+/HER2- ABC with or without PIK3CA..."

Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • ER • HER-2 • PIK3CA

INAVO120: Inavolisib Triplet Improves PFS in PIK3CA-, ESR1-, and TP53-Mutated HR+/HER2– Breast Cancer (DocWire) - "After PIK3CA mutations, the most common genomic alterations in the study population were TP53 (49.4%), CDH1 (17.6%), ESR1 (14.5%), and PTEN (10.9%). In addition, 20.3% of patients carried multiple PIK3CA mutations. Patients with a tumor fraction higher than the median of 3.8% had worse progression-free survival (PFS) in both the intervention (hazard ratio [HR], 1.9; 95% CI, 1.2-3.1) and control (HR, 1.8; 95% CI, 1.2-2.7) study arms. The effect of triplet therapy on PFS was similarly beneficial among patients with (HR, 0.2; 95% CI, 0.1-0.7) and without (HR, 0.5; 95% CI, 0.4-0.7) ESR1 short variant mutations (P=0.705)."

Biomarker • P2/3 data • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer

Caprine herpes virus-1 reduces cell viability and enhances chemosensitivity in breast cancer cells. (PubMed, Front Oncol) - "Additionally, CpHV-1 was tested in combination with Abemaciclib, Tucatinib, and Inavolisib, and synergism was evaluated using Chou-Talalay analysis. These findings highlight CpHV-1 as a promising oncolytic agent capable of targeting multiple breast cancer subtypes. Its ability to significantly reduce viability, impair long-term proliferation, and induce apoptosis, together with its synergistic activity when combined with FDA-approved targeted therapies and its limited toxicity in normal cells, supports further investigation of CpHV-1 for breast cancer treatment."

Journal • Breast Cancer • Infectious Disease • Oncology • Solid Tumor

INAVO123: Phase 3 study of first-line inavolisib / placebo + a cyclin-dependent kinase 4/6 inhibitor + letrozole in participants with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-sensitive advanced breast cancer (SABCS 2025) - P2/3 | "BACKGROUNDStandard of care for PIK3CA-mutated (mut), hormone receptor-positive (HR+), HER2-negative (HER2-), endocrine-sensitive advanced breast cancer (aBC) is endocrine therapy + a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i), but progression is expected due to resistance.Inavolisib (INAVO) is a highly potent and selective PI3Kαi that also promotes degradation of mut p110α.INAVO120 (NCT04191499) showed that first-line (1L) treatment with INAVO + palbociclib (PALBO) + fulvestrant (FULV) resulted in a significantly improved progression-free survival (PFS) benefit vs placebo (PBO) + PALBO + FULV (stratified hazard ratio 0.43; 95% confidence interval 0.32-0.59; p < 0.0001) in patients with PIK3CAmut, HR+, HER2-, endocrine-resistant aBC, and is now approved by the Food and Drug Administration for use in such patients.TRIAL DESIGNINAVO123 evaluates 1L INAVO + a CDK4 / 6i + letrozole (LET) vs PBO + a CDK4 / 6i + LET in participants (pts) with PIK3CAmut..."

Clinical • Metastases • P3 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2 • PIK3CA

Interim safety in the inavolisib + ribociclib or abemaciclib + fulvestrant or letrozole arms of MORPHEUS-pan breast cancer: A Phase 1b/2 study of efficacy and safety of multiple treatment combinations in patients with advanced breast cancer (SABCS 2025) - P1/2, P2/3 | "In INAVO120 (NCT04191499), adding inavolisib (INAVO), a highly potent, oral, selective PI3Kαi, to fulvestrant (FULV) + palbociclib significantly improved progression-free and overall survival vs placebo in pts with PIK3CA-mutated, HR+, HER2-, endocrine-resistant aBC. The combinations were tolerable, supporting further investigation. Updated data, including pharmacokinetics and data from additional pts, including those treated with INAVO + ABEMA + LET, will be presented."

Clinical • Metastases • P1/2 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ER • HER-2 • PIK3CA

Gper signaling as a biomarker for endocrine therapy sensitivity in pik3ca mutant hr+ advanced breast cancer (SABCS 2025) - "In GPERhigh tamoxifen-resistant cells, combinations of inavolisib with abemaciclib or ribociclib exhibited superior antiproliferative effects compared to palbociclib-based regimens, which assessed by MTT assays, flow cytometry for apoptosis, and cell cycle analysis. Therefore, assessing GPER signaling activation in tumor biopsies may enable precise identification of PIK3CA-mutant HR+ advanced breast cancer patients likely to benefit from specific endocrine and targeted therapy combinations. Integrating PI3K, CDK4/6, and GPER-targeted therapies represents a promising strategy to overcome endocrine resistance in the future, offering a path toward personalized treatment paradigms with improved clinical outcomes."

Biomarker • Metastases • Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ABCG2 • PIK3CA

Molecular features of response to palbociclib + fulvestrant ± inavolisib in hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer as assessed from baseline circulating tumor DNA in the pivotal Phase 3 INAVO120 trial (SABCS 2025) - P2/3 | "Although sample sizes were small, subgroup analyses in pts with a PTENmut did not conclusively suggest lack of benefit of this INAVO regimen vs PBO. Overall, these post-hoc, exploratory findings warrant further investigation in larger datasets."

Circulating tumor DNA • Metastases • P3 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • CDH1 • ER • HER-2 • PIK3CA • PTEN • TP53

Comparative analysis of blood- and tissue-based PIK3CA mutation detection methods in the pivotal Phase 3 INAVO120 trial of palbociclib + fulvestrant ± inavolisib in hormone receptor-positive, HER2-negative advanced breast cancer (SABCS 2025) - P2/3 | "PPA ([Cobas+ and F1CDx+] / F1CDx+), NPA ([Cobas- and F1CDx-] / F1CDx-), and OPA were 90.2% (46 / 51), 100% (33 / 33), and 94.0% (79 / 84), respectively. With regard to efficacy, pts enrolled by a local test (hazard ratio for progression-free survival [PFS] 0.7; 95% CI 0.3-1.5; n = 39) or the F1LCDx central test (hazard ratio for PFS 0.5; 95% CI 0.3-0.7; n = 242) showed a similar response to inavolisib plus palbociclib and fulvestrant over placebo plus palbociclib and fulvestrant.CONCLUSIONSThis comprehensive concordance analysis utilizing INAVO120 specimens demonstrated the ability of both tissue- and blood-based PCR and next-generation sequencing assays to robustly identify a pt population with PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced BC who may consistently benefit from this INAVO-based regimen."

Biomarker • Metastases • P3 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2 • PIK3CA

Associations Between Circulating Tumor DNA Genomic Profiles and Serum Thymidine Kinase Patterns in Patients with Advanced, Hormone Receptor-Positive, HER2-Negative (HR+/HER-) Breast Cancer Initiating Treatment with a CDK4/6 Inhibitor (CDK4/6i) (SABCS 2025) - P=N/A | "This case series evaluates TKa patterns in relation to baseline circulating tumor DNA (ctDNA) profiles in patients with HR+/HER2- metastatic BC (MBC) treated with a CDK4/6i and ET. We evaluated a group of patients from two cancer centers with HR+/HER2- MBC initiating treatment with a CDK4/6i (ribociclib, abemaciclib, palbociclib) and ET (an aromatase inhibitor/AI or the selective estrogen receptor degrader/SERD, fulvestrant)...Another patient with RB1 loss and multiple co-occurring mutations (ESR1, PIK3CA, KRASG12V, ATM and BRCA2 loss) had a reduction in TKa from 242 at baseline to 68 at C2D1 after starting palbociclib, inavolisib, and fulvestrant. TKa is a novel biomarker with important clinical implications... TKa is a novel biomarker with important clinical implications. Understanding the genomic drivers underlying treatment response is an area of active investigation. This hypothesis-generating study compares baseline ctDNA profiles with TKa response patterns..."

Circulating tumor DNA • Clinical • Metastases • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • BRCA2 • CCNE1 • CDK4 • CHEK2 • ER • FGFR1 • HER-2 • KRAS • PIK3CA • PTEN • RB1

Relationship of early ctDNA dynamics with response to inavolisib alone or in combination with endocrine therapy +/- CDK4/6 inhibitor in PIK3CA-mutated HR+, HER2- metastatic breast cancer from the first-in-human phI/Ib trial (SABCS 2025) - P1 | "Together, our results suggest that early changes in ctDNA, specifically the % change in PIK3CA VAF between baseline and C1D15, are associated with objective response to inavolisib-containing regimens and may enable early stratification of patient response that is ultimately predictive of PFS. Additional research with larger cohorts and encompassing the evaluation of tumor fraction (not available for this dataset) are warranted to confirm these findings and to understand the applicability to other targeted therapies for HR+, HER2- breast cancer."

Circulating tumor DNA • Combination therapy • First-in-human • Metastases • P1 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2 • PIK3CA

The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 26 November 2025, approved inavolisib (Itovebi) for the treatment of adults with a type of breast cancer called HR-positive, HER2-negative breast cancer. (GOV.UK) - "Inavolisib is licensed for adults whose breast cancer has come back, during or soon after hormone therapy, and has spread to other parts of the body. It will be available to patients whose cancer has specific changes in its genes and is not suitable for those who have recently had certain other cancer treatments."

MHRA approval • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer

A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Neoadjuvant Therapy With Inavolisib Plus Pertuzumab and Trastuzumab as Subcutaneous (PH-FDC SC) and 3-week Cycle Nab-paclitaxel for PIK3CA-mutated, HER2+, eBC (clinicaltrials.gov) - P2 | N=164 | Not yet recruiting | Sponsor: Zhimin Shao

New P2 trial • Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor

Mechanistic optimization of inavolisib combined with CDK4/6 inhibitors in the treatment of PIK3CA-mutated breast tumors. (PubMed, Front Immunol) - P2/3 | "CDK4/6 inhibitors (such as palbociclib and ribociclib) block the transition from the G1 to S phase of the cell cycle and have become standard treatment for hormone receptor-positive breast cancer. It covers molecular mechanisms, synergistic effects, resistance strategies, biomarkers, and future directions, with an emphasis on immunological implications. The scope is limited to HR+/HER2-negative subtypes, excluding other cancers or non-PI3K-targeted therapies, to provide a focused foundation for translational immunology in oncology."

Journal • Review • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2 • PIK3CA

A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: Hoffmann-La Roche | Trial primary completion date: Mar 2027 ➔ Jul 2027

Trial primary completion date • Breast Cancer • Estrogen Receptor Positive Breast Cancer • HER2 Negative Breast Cancer • Oncology • Solid Tumor

The Case of the Vanishing Natrium: Phosphoinositide 3-Kinase Inhibitor Did It! (KIDNEY WEEK 2025) - "Case Description 74-year-old woman with history of stage 4 breast cancer, estrogen receptor positive, HER 2 negative, with phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutation previously on chemotherapy (Anastrozole and palbociclib; capivasertib and fulvestrant) and radiotherapy developed progressive bone and pulmonary metastatic lesions. Due to side effects, her chemotheray was switched to inavolisib, palbociclib and fulvestrant...This case highlights the importance of close monitoring of sodium levels in cancer patients on such therapies. Laboratory Studies Sodium trend during the hospital stay"

Clinical • IO biomarker • Breast Cancer • Estrogen Receptor Positive Breast Cancer • Heart Failure • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Otorhinolaryngology • Solid Tumor • ER • HER-2 • PIK3CA